 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Rigel Pharmaceuticals, Inc.
 |
Rigel Pharmaceuticals, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Rigel in deal with Novartis to find cancer drugs Jul 31 2001 08:28 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
When immune systems attack, Rigel Pharmaceuticals wants to be there. The development-stage firm has a dozen research programs for such targets as asthma, allergy, hepatitis C, transplant rejection, chronic bronchitis, tumors, and such autoimmune conditions as rheumatoid arthritis and inflammatory bowel disease. It uses retroviruses to induce a disease-like response in cells, allowing for easier identification of targets for drug discovery. Rigel has collaborations with Cell Genesys; Janssen Pharmaceutica, a Johnson & Johnson unit; Novartis; and Pfizer.
COMPETITION |
 |
Aventis (AVE)
Centocor, Inc. (dossier)
Immunex Corporation (IMNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 13.20
1-Yr. Sales Growth: 46.7%
Employees: 107
Revenue per employee: $123,364.49
KEY PEOPLE |
 |
James M. Gower
CEO
Brian C. Cunningham
CFO
CONTACT INFO |
 |
240 E. Grand Ave.
South San Francisco, CA 94080
US
Phone: 650-624-1100
Fax: 650-624-1101
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |